DIRAS3 and glioma: Based on published research and our findings, we hypothesize a dual-mode mechanism: (1) BST2/DIRAS3 may activate pro-invasive signaling pathways intrinsically within glioma cells; (2) their functional synergy within the tumor microenvironment (TME) potentially establishes systemic immune evasion, particularly against CD8+ T-cell-mediated antitumor immunity.